Trial
NCT01402908
A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical Resection
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Cellxpert Biotechnology Corp.
Collaborators
Medigen Biotechnology Corporation
Condition
Cancer
Intervention
PI-88
Why stopped
Due to Interim Analysis and business concerns
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-06-23